Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval

Executive Summary

The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.

You may also be interested in...



Lupus Pipeline Could See Momentum Following Two New US Approvals

Albert Roy, executive director of the clinical research arm of the Lupus Research Alliance, talked to Scrip about the outlook for lupus drug development.

New Lupus Nephritis Treatments Are Cost Effective, ICER Determines

GSK's Benlysta and Aurinia's Lupkynis for lupus nephritis are priced in line with the drug pricing watch dog's health benefit price benchmark ranges.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel